Stock 688553 SICHUAN HUIYU PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Sichuan Huiyu Pharmaceutical Co., Ltd. Stock

Equities

688553

CNE100004ZT4

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
14.09 CNY +7.97% Intraday chart for Sichuan Huiyu Pharmaceutical Co., Ltd. +14.37% -6.87%
Apr. 17 Sichuan Huiyu Pharmaceutical Gets Chinese FDA Nod for Methotrexate Anti-Tumor Injection MT
Apr. 02 Tranche Update on Sichuan Huiyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 24, 2024. CI

Financials

Sales 2021 1.82B 252M Sales 2022 1.49B 206M Capitalization 6.6B 912M
Net income 2021 446M 61.6M Net income 2022 249M 34.39M EV / Sales 2021 6.19 x
Net cash position 2021 2.95B 407M Net cash position 2022 2.53B 349M EV / Sales 2022 2.73 x
P/E ratio 2021
28 x
P/E ratio 2022
26.4 x
Employees 1,669
Yield 2021
0.63%
Yield 2022
1.51%
Free-Float 39.27%
More Fundamentals * Assessed data

Chart Sichuan Huiyu Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Sichuan Huiyu Pharmaceutical Co., Ltd.

Sichuan Huiyu Pharmaceutical Gets Chinese FDA Nod for Methotrexate Anti-Tumor Injection MT
Tranche Update on Sichuan Huiyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 24, 2024. CI
Huiyu Pharma Unit Gets Libya's Marketing Approval for Cancer Drug MT
Huiyu Pharma Gets China Registration Approval for Cancer Drug MT
US FDA Grants New Drug Application to Huiyu Pharma's Cancer Injection MT
Sichuan Huiyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares. CI
Sichuan Huiyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sichuan Huiyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Three Drugs of Huiyu Pharma's Unit Gets Greenlight to Enter Egyptian Market MT
Huiyu Pharma's Unit Gets Greenlight to Enter UK Market MT
Huiyu Pharmaceutical's Subsidiary Administers First Patient for Tumor Drug Trial; Shares Drop 5% MT
TYK Medicines, Inc. announced that it has received funding from Sichuan Huiyu Pharmaceutical Co., Ltd., CICC Capital Management Co., Ltd., Zhejiang Changxing Financial Holding Group Co., Ltd., and other investors CI
Huiyu Pharma Passes US FDA Inspection MT
Chengdu Houhan Technology Co., Ltd. and Beijing Houhong Technology Co., Ltd. agreed to acquire 49.9% stake in Sichuan Huiyu Yueying Pharmaceutical Technology Co., Ltd. from Sichuan Huiyu Pharmaceutical Co., Ltd. for CNY 16.6 million. CI
Huiyu Pharmaceutical's Methotrexate for Injection Passes Regulatory Evaluation MT
More news

Quotes and Performance

1 day+7.97%
1 week+14.37%
Current month+2.62%
1 month+2.62%
3 months+17.61%
6 months-4.47%
Current year-6.87%
More quotes

Highs and lows

1 week
12.41
Extreme 12.41
14.20
1 month
11.92
Extreme 11.92
14.20
Current year
9.45
Extreme 9.45
15.42
1 year
9.45
Extreme 9.45
17.12
3 years
9.45
Extreme 9.45
42.59
5 years
9.45
Extreme 9.45
42.59
10 years
9.45
Extreme 9.45
42.59
More quotes

Managers and Directors - Sichuan Huiyu Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Zhao Ding CEO
 Chief Executive Officer 39 10-10-11
Lan Gao DFI
 Director of Finance/CFO 53 19-10-13
Li Na Ma BRD
 Director/Board Member 48 22-04-30
Members of the board TitleAgeSince
Li Na Ma BRD
 Director/Board Member 48 22-04-30
Lan Gao DFI
 Director of Finance/CFO 53 19-10-13
Zhao Ding CEO
 Chief Executive Officer 39 10-10-11
More insiders

Quotes

Date Price Change Volume
24-04-29 14.09 +7.97% 3,559,969
24-04-26 13.05 +2.27% 1,223,316
24-04-25 12.76 +1.75% 1,708,904
24-04-24 12.54 +0.40% 857,396
24-04-23 12.49 +1.38% 1,192,131

End-of-day quote Shanghai S.E., April 28, 2024

More quotes

Company Profile

Sichuan Huiyu Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of anti-tumor and injection drugs. The Company’s products are mainly anti-tumor chemical injections, including pemetrexed disodium for injection, docetaxel injection, zoledronic acid injection, irinotecan hydrochloride injection, doxorubicin hydrochloride injection liquid and azacitidine for injection. The Company's products are mainly used in the clinical treatment of various adaptive diseases. The Company distributes its products both in the domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
SICHUAN HUIYU PHARMACEUTICAL CO., LTD. Stock Sichuan Huiyu Pharmaceutical Co., Ltd.
-6.87% 763M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688553 Stock